Incidence of infusion-related reactions in patients receiving infliximab.

被引：0
|
作者：
Buch, MH [1 ]
Bryer, D [1 ]
Fairclough, A [1 ]
ReesEvans, B [1 ]
Emery, P [1 ]
机构：
[1] Univ Leeds, Acad Unit Musculoskeletal Dis, Leeds LS2 9JT, W Yorkshire, England
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
771
引用
收藏
页码：S325 / S325
页数：1
相关论文
共 50 条
  • [1] Incidence of infusion-related reactions in patients receiving infliximab: Recommendations for administration guidelines
    Buch, MH
    Lindsay, S
    Bryer, D
    Fairclough, A
    Rees-Evans, B
    Emery, P
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 285 - 285
  • [2] Incidence of infusion-related reactions with infliximab: effect of pretreatment.
    Gerlach, AT
    Sierawski, SJ
    Hollis, H
    [J]. PHARMACOTHERAPY, 2002, 22 (10): : 1326 - 1326
  • [3] Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease
    Rusch, Caroline
    Wood, Marci
    Kennedy, Amanda G.
    Tompkins, Bradley J.
    Frasca, Joseph D.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1851 - 1857
  • [4] Management of infusion-related reactions (IRRs) in patients receiving amivantamab
    Park, K.
    Sabari, J. K.
    Haura, E. B.
    Shu, C. A.
    Spira, A.
    Salgia, R.
    Reckamp, K. L.
    Sanborn, R. E.
    Govindan, R.
    Bauml, J. M.
    Curtin, J. C.
    Xie, J.
    Roshak, A.
    Lorenzini, P.
    Millington, D.
    Thayu, M.
    Knoblauch, R. E.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S981 - S982
  • [5] Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab
    Thompson, Lisa M.
    Eckmann, Karen
    Boster, Bonnie L.
    Hess, Kenneth R.
    Michaud, Laura B.
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    Barnett, Chad M.
    [J]. ONCOLOGIST, 2014, 19 (03): : 228 - 234
  • [6] Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
    Park, Keunchil
    Sabari, Joshua
    Haura, Eric B.
    Shu, Catherine A.
    Spira, Alexander
    Salgia, Ravi
    Reckamp, Karen L.
    Sanborn, Rachel E.
    Govindan, Ramaswamy
    Bauml, Joshua M.
    Curtin, Joshua C.
    Xie, John
    Roshak, Amy
    Lorenzini, Patricia
    Millington, Dawn
    Thayu, Meena
    Knoblauch, Roland E.
    Cho, Byoung Chul
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S482 - S482
  • [7] Incidence and Management of Olaratumab Infusion-Related Reactions
    Van Tine, Brian A.
    Govindarajan, Rangaswamy
    Attia, Steven
    Somaiah, Neeta
    Barker, Scott S.
    Shahir, Ashwin
    Barrett, Emily
    Lee, Pablo
    Wacheck, Volker
    Ramage, Samuel C.
    Tap, William D.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (11) : 592 - +
  • [8] Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
    Loirat, Delphine
    Logeart, Juliette
    Vaflard, Pauline
    Noret, Aurelien
    Saint-Ghislain, Mathilde
    Borcoman, Edith
    Hurgon, Audrey
    Cros, Cyrille
    Genevee, Thomas
    Bellesoeur, Audrey
    Ricci, Francesco
    Lerebours, Florence
    Escalup, Laurence
    Sablin, Marie-Paule
    Bidard, Francois-Clement
    Cottu, Paul H.
    Pierga, Jean-Yves
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [9] Anti-infliximab antibodies in patients with an infusion related allergic response to infliximab.
    Wolbink, G
    de Groot, E
    Lems, W
    Dijkmans, B
    Nurmohamed, M
    Tak, PP
    Voskuyl, A
    Aarden, L
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S326 - S326
  • [10] Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab
    Dawson, Keith
    Moran, Mollie
    Guindon, Kathleen
    Wan, Hui
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (02) : E41 - E48
12345